IE stock · Healthcare sector · Medical Devices
Company Logo

Medtronic plc

MDTNYSE

86.58

USD
+1.34
(+1.57%)
Market Closed
26.52P/E
16Forward P/E
1.20P/E to S&P500
115.167BMarket CAP
3.07%Div Yield
Upcoming Earnings
21 Feb
Shares Short
1/13/23
11.85M
Short % of Float
0.89%
Short % of Shares Outs.
0.89%
% Held by Insiders
0.09%
% Held by Institutions
84.89%
Beta
0.72
PEG Ratio
5.97
52w. high/low
114.31/75.77
Avg. Daily Volume
7.73M
Return %
Stock
S&P 500
1 year
(15.07)
(7.99)
3 years
(27.77)
23.80
5 years
8.10
56.27
Scale: |
High
Low
56.97
28.33
44.94
24.06
46.66
30.80
43.33
30.18
44.79
35.67
58.85
41.16
75.66
53.33
79.50
55.54
89.27
71.03
89.72
69.35
100.15
76.41
115.94
81.66
122.15
72.13
135.89
98.38
114.31
75.77
87.85
77.38
Currency: USD
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
Revenue per share
10.70
11.95
13.06
14.30
14.79
15.36
16.28
16.97
18.49
20.45
21.55
22.08
22.70
21.57
22.39
23.60
23.08
Earnings per share
2.44
1.97
1.94
2.80
2.87
3.43
3.40
3.06
2.44
2.51
2.92
2.29
3.44
3.57
2.68
3.75
3.23
FCF per share
1.99
2.55
2.88
3.16
2.96
3.77
4.34
4.55
3.95
2.96
4.08
2.67
4.36
4.49
3.63
4.45
3.61
Dividends per share
0.44
0.50
0.75
0.82
0.90
0.97
1.04
1.11
1.22
1.52
1.72
1.84
2.00
2.16
2.32
2.52
2.62
CAPEX per share
0.60
0.54
0.59
0.57
0.51
0.47
0.45
0.40
0.52
0.74
0.91
0.79
0.84
0.90
1.01
1.02
1.10
Book Value per sh.
9.55
10.20
11.50
13.22
14.82
16.24
18.32
19.40
48.59
36.93
36.47
37.38
37.20
37.84
38.24
39.15
39.26
Comm.Shares outs.
1,150
1,131
1,118
1,106
1,077
1,054
1,019
1,002
1,096
1,410
1,379
1,357
1,346
1,341
1,345
1,342
1,335
Avg. annual P/E ratio
21.2
23.7
18.0
13.9
12.9
11.6
15.1
20.6
30.4
31.9
27.8
38.4
28.7
28.6
45.3
25.2
26.5
P/E to S&P500
1.2
1.1
0.3
0.7
0.8
0.8
0.9
1.1
1.5
1.4
1.2
1.5
1.2
0.8
1.5
1.2
1.2
Avg. annual div. yield
0.8%
1.1%
2.2%
2.1%
2.4%
2.4%
2.0%
1.8%
1.6%
1.9%
2.1%
2.1%
2.0%
2.1%
1.9%
2.7%
2.9%
Revenue (m)
12,299
13,515
14,599
15,817
15,933
16,184
16,590
17,005
20,261
28,833
29,710
29,953
30,557
28,913
30,117
31,686
30,808
Operating margin
30.4%
30.2%
28.6%
27.1%
28.4%
29.9%
28.8%
28.3%
18.6%
18.4%
17.9%
22.2%
20.5%
16.6%
14.9%
18.2%
19.0%
Depreciation (m)
583
637
699
772
804
833
819
850
1,306
2,820
2,917
2,644
2,659
2,663
2,702
2,707
2,699
Net profit (m)
2,802
2,231
2,169
3,099
3,096
3,617
3,467
3,065
2,675
3,538
4,028
3,104
4,631
4,789
3,606
5,039
4,321
Income tax rate
20.3%
22.7%
16.4%
21.9%
16.8%
17.6%
18.4%
17.3%
23.3%
18.4%
12.6%
45.5%
10.5%
(18.5)%
6.8%
8.3%
23.3%
Net profit margin
22.8%
16.5%
14.9%
19.6%
19.4%
22.3%
20.9%
18.0%
13.2%
12.3%
13.6%
10.4%
15.2%
16.6%
12.0%
15.9%
13.9%
Working capital (m)
5,355
3,787
4,313
4,718
4,403
3,658
13,902
15,651
21,671
16,435
10,653
12,896
13,495
11,665
14,039
10,665
10,933
Long-term debt (m)
5,578
5,802
6,772
6,944
8,112
7,359
9,560
10,259
33,673
30,158
25,881
23,705
24,477
22,021
26,378
20,372
20,753
Equity (m)
10,977
11,536
12,851
14,629
15,968
17,113
18,671
19,443
53,230
52,063
50,294
50,720
50,091
50,737
51,428
52,551
51,880
ROIC
16.5%
12.0%
11.5%
14.9%
13.5%
14.2%
12.2%
10.4%
3.3%
5.0%
5.8%
4.6%
7.3%
7.6%
5.3%
7.1%
6.0%
Return on capital
18.0%
13.0%
11.9%
15.6%
13.7%
14.2%
13.3%
10.8%
3.9%
5.7%
5.7%
7.5%
7.4%
5.7%
5.2%
6.7%
6.6%
Return on equity
25.5%
19.3%
16.9%
21.2%
19.4%
21.1%
18.6%
15.8%
5.0%
6.8%
8.0%
6.1%
9.2%
9.4%
7.0%
9.6%
8.3%
Plowback ratio
82.0%
74.7%
61.1%
70.7%
68.7%
(Infinity)%
69.6%
63.6%
50.0%
39.5%
41.0%
19.4%
42.1%
39.8%
14.0%
33.2%
19.5%
Div.&Repurch./FCF
53.0%
59.2%
36.9%
50.7%
63.4%
59.6%
46.0%
51.8%
60.2%
107.3%
97.6%
117.9%
77.9%
59.1%
67.5%
92.0%
113.4%
Capital Structure
1 Dec · 2022 | Q2
All numbers in millions
Total liabilities
$ 41,184
Total assets
$ 93,241
Long-term debt
$ 20,753
Cash and equiv.
$ 4,828
Goodwill
$ 40,417
Retained earnings
$ 29,799
Common stock
1,329
Enterprise Value
$ 131,092
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
10,948
10,817
10,573
Receivables
4,645
5,462
5,551
Inventory
4,229
4,313
4,616
Other
2,209
1,409
1,893
Current assets
22,031
22,548
23,059
Acc. Payable
1,996
2,106
2,276
Debt due
2,776
11
3,742
Other
5,594
6,392
6,376
Current liabilities
10,366
8,509
12,394
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
5.21%
1.50%
8.20%
Cash flow
22.37%
17.11%
6.88%
Earnings
39.74%
16.91%
7.39%
Dividends
8.43%
7.92%
14.81%
Book value
2.18%
0.90%
19.64%
Insider Trading
Type
Shares
Date
Kirk Jennifer M
InKind
672
02/01/23
Salmon Sean
Exempt
14,823
12/13/22
Salmon Sean
Sale
16,631
12/13/22
Salmon Sean
Exempt
14,823
12/13/22
Salmon Sean
Exempt
1,808
12/13/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2021
6,507
7,647
7,775
8,188
30,117
2022
7,987
7,847
7,763
8,089
31,686
2023
7,371
7,585
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
0.36
0.36
0.94
1.01
2.68
2022
0.57
0.98
1.10
1.11
3.75
2023
0.70
0.32
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
0.58
0.58
0.58
0.58
2.32
2022
0.63
0.63
0.63
0.63
2.52
2023
0.68
0.68
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Medical Devices
CEO:
Mr. Omar Ishrak
Full-time employees:
95,000
City:
DUBLIN
Address:
20 On Hatch, Hatch Street Lower
IPO:
Mar 17, 1980
Website:
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Recent News